MPSLTD MPS Q4 FY26 results (Jan–Mar 2026) and concall
MPS reported its most profitable year in FY26, driven by strong Q4 performance and robust organic growth across Research and Education segments. The company's AI-first knowledge management strategy is yielding margin expansion and operational leverage. While Corporate Learning saw a reset in FY25, it showed an inflection in Q4 FY26. The company is confident in crossing INR 300 crores in EBITDA for FY27, supported by the Unbound Medicine acquisition and a healthy pipeline, though no dividend was declared due to ongoing capital deployment.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 26.6%, net profit up 63.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 87 | 90 | 94 | 100 | 111 +28% | 108 +20% | 119 +27% |
| EBITDA | 35 | 34 | 35 | 34 | 44 +26% | 41 +21% | 48 +37% |
| Net profit | 27 | 29 | 27 | 29 | 30 +11% | 25 −14% | 44 +63% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
